Discover the most talked about and latest scientific content & concepts.

MB Leon, CR Smith, MJ Mack, RR Makkar, LG Svensson, SK Kodali, VH Thourani, EM Tuzcu, DC Miller, HC Herrmann, D Doshi, DJ Cohen, AD Pichard, S Kapadia, T Dewey, V Babaliaros, WY Szeto, MR Williams, D Kereiakes, A Zajarias, KL Greason, BK Whisenant, RW Hodson, JW Moses, A Trento, DL Brown, WF Fearon, P Pibarot, RT Hahn, WA Jaber, WN Anderson, MC Alu and JG Webb
Background Previous trials have shown that among high-risk patients with aortic stenosis, survival rates are similar with transcatheter aortic-valve replacement (TAVR) and surgical aortic-valve replacement. We evaluated the two procedures in a randomized trial involving intermediate-risk patients. Methods We randomly assigned 2032 intermediate-risk patients with severe aortic stenosis, at 57 centers, to undergo either TAVR or surgical replacement. The primary end point was death from any cause or disabling stroke at 2 years. The primary hypothesis was that TAVR would not be inferior to surgical replacement. Before randomization, patients were entered into one of two cohorts on the basis of clinical and imaging findings; 76.3% of the patients were included in the transfemoral-access cohort and 23.7% in the transthoracic-access cohort. Results The rate of death from any cause or disabling stroke was similar in the TAVR group and the surgery group (P=0.001 for noninferiority). At 2 years, the Kaplan-Meier event rates were 19.3% in the TAVR group and 21.1% in the surgery group (hazard ratio in the TAVR group, 0.89; 95% confidence interval [CI], 0.73 to 1.09; P=0.25). In the transfemoral-access cohort, TAVR resulted in a lower rate of death or disabling stroke than surgery (hazard ratio, 0.79; 95% CI, 0.62 to 1.00; P=0.05), whereas in the transthoracic-access cohort, outcomes were similar in the two groups. TAVR resulted in larger aortic-valve areas than did surgery and also resulted in lower rates of acute kidney injury, severe bleeding, and new-onset atrial fibrillation; surgery resulted in fewer major vascular complications and less paravalvular aortic regurgitation. Conclusions In intermediate-risk patients, TAVR was similar to surgical aortic-valve replacement with respect to the primary end point of death or disabling stroke. (Funded by Edwards Lifesciences; PARTNER 2 number, NCT01314313 .).
Facebook likes*
News coverage*
SC clicks
Medical terms, Blood transfusion, Atrial flutter, Surgery, Aortic valve stenosis, Randomness, Epidemiology, Atrial fibrillation
MeSH headings
comments powered by Disqus

* Data courtesy of